Abstract
Twenty-two patients with primary lung cancer were treated with combination chemotherapy using Cis-diamminedichloroplatinum (CDDP), Cyclophosphamide (CTX) and Vincristirle (VCR). Small cell carcinoma was more responsive than non-small cell carcinoma, with response rates of 88.9% and 23.1%, respectively.
All patients were divided into two groups. In one group (Type I), CDDP was given at 20 mg/m2 per day for five consecutive days, and in the other group (Type II), CDDP was given at 80 mg/m2 at one time.
No difference was detected in the degree of nausea and vomiting, but their duration is much longer in Type I. Therefore, we concluded that Type II was superior to Type I from this viewpoint. Subclinical renal damage was seen in three patients, so that the limitation of total given dose of CDDP must be considered.
